Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Webcast

4D Pharma to Present at Upcoming Investor Conferences in March


4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences:

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma (NCT03851250), a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 (NCT04363372), and Blautix® in Irritable Bowel Syndrome (IBS) (NCT03721107) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

In October 2020 4D pharma announced its intention to merge with Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose acquisition company (SPAC), and seek a NASDAQ listing. The merger is expected to be completed and the NASDAQ listing of 4D pharma American Depositary Shares (ADSs) under the ticker symbol 'LBPS' is currently expected to become effective in early 2021, subject to the satisfaction of closing conditions, including approval of 4D shareholders and Longevity shareholders and the approval by Nasdaq of the listing of ADSs.

For more information, refer to www.4dpharmaplc.com.

Forward-Looking Statements

This press release contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding participation in investor conferences are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including the risks of delays in the commencement of the clinical trial and those additional risks and uncertainties described the documents filed by the Company with the US Securities and Exchange Commission ("SEC"), should be carefully considered. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.


These press releases may also interest you

at 08:10
Data Theorem, Inc., a leading provider of modern application security, today announced that its Web Secure AppSec solution has earned a 2021 The Govies Government Security Award from Security Today magazine, the only integrated product and technology...

at 08:10
The "Hemoglobin A1C Monitoring - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Hemoglobin A1C Monitoring Market to Reach $1.7 Billion by 2027 Amid the COVID-19 crisis, the global market...

at 08:10
Integrated Specialty Coverages ("ISC" or the "Company"), a leading, multi-line program administrator that builds end-to-end insurance products utilizing advanced artificial intelligence (AI) engineering and data analytics, today announced the launch...

at 08:10
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that it has granted Cooper International and United PPE licenses...

at 08:10
April 21, 2021 -- New Gold Inc. ("New Gold" or the "Company") today announces that three employees at the Rainy River Mine in northwestern Ontario received positive COVID-19 test results. An additional seven employees have tested non-negative with...

at 08:10
Perception Point, a leading email and collaboration security company, offering fast interception of content-based attacks as a service, announced today it has raised $28 million in Series B, bringing the total funding to $48 million. The new funding...



News published on 3 march 2021 at 07:05 and distributed by: